Transmedics Group Inc (NASDAQ: TMDX) closed the day trading at $93.31 up 1.62% from the previous closing price of $91.82. On the day, 848825 shares were traded.
Ratios:
For a better understanding of TMDX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 3.76 whereas as Long-Term Debt/Eq ratio is at 3.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on March 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $95.
JP Morgan Upgraded its Neutral to Overweight on August 02, 2022, while the target price for the stock was maintained at $48.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 10 ’24 when Hassanein Waleed H sold 12,000 shares for $95.09 per share. The transaction valued at 1,141,080 led to the insider holds 74,087 shares of the business.
Khayal Tamer I sold 15,512 shares of TMDX for $1,403,082 on Apr 09 ’24. The Chief Commercial Officer now owns 25,185 shares after completing the transaction at $90.45 per share. On Apr 08 ’24, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 4,388 shares for $90.00 each. As a result, the insider received 394,920 and left with 25,185 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 12.64 while its Price-to-Book (P/B) ratio in mrq is 22.22.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $36.42.
Shares Statistics:
A total of 32.67M shares are outstanding, with a floating share count of 31.48M. Insiders hold about 3.79% of the company’s shares, while institutions hold 109.02% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of $0.11 and a low estimate of -$0.33, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.04, with high estimates of $0.28 and low estimates of -$0.37.
Analysts are recommending an EPS of between $0.56 and -$1.24 for the fiscal current year, implying an average EPS of -$0.23. EPS for the following year is $0.32, with 5 analysts recommending between $1.55 and -$0.9.
Revenue Estimates
6 analysts predict $83.78M in revenue for the current quarter. It ranges from a high estimate of $85.5M to a low estimate of $81.2M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $41.55M, an estimated increase of 101.60% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $372.4M, while the lowest revenue estimate was $360M, resulting in an average revenue estimate of $366.99M. In the same quarter a year ago, actual revenue was $241.62M, up 51.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $489.97M in the next fiscal year. The high estimate is $539.8M and the low estimate is $450.14M. The average revenue growth estimate for next year is up 33.50% from the average revenue estimate for this year.
